Clinical Trial Update: GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating GS-5885 (ledipasvir) alone or with GS-9451 in combination with peginterferon alfa-2a and ribavirin for chronic hepatiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9451 (GS-9451)
• Ledipasvir (GS-5885) (Ledipasvir)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED